To develop an effective and safe HER2+ breast cancer vaccine, researchers must first better understand the tumor microenvironment, identify specific tumor-associated antigens, develop effective vaccine formulations, and determine the best route of administration [413]. The gene discussed is ERBB2; the disease is neoplasm.